Remington’s, Stedman’s, Goodman & Gilman’s, Harrison’s, and Koda-Kimble—a few textbooks in the medical and pharmacy fields have become so well known that students often refer to them by the name of a chief editor or author rather than book titles.
This book, Pharmacotherapy: A Pathophysiologic Approach, quickly reached that stature in pharmacy education and practice following the publication of the first edition in 1988. By changing our title to DiPiro’s Pharmacotherapy with this 12th edition, we make permanent the association of this work with the important leadership and vision of our founding editor, Joseph T. DiPiro, PharmD, who had the initial discussions with our original publisher, Elsevier, in 1983. By 1985, a cohesive team of founding editors came together with a unified vision of pharmacotherapy and how it fit into the practice of clinical pharmacy. DiPiro, along with Michael Posey, Robert Talbert, Peggy Hayes, and Gary Yee, took on the difficult chore of identifying more than 200 recognized experts from across the United States who would write, from scratch, 111 chapters. Just two years later, the team began to funnel chapters to the publisher and through to publication.
Gary Matzke, after serving as an author and section editor in the first edition, joined the masthead for the second edition, and Barbara Wells replaced Peggy Hayes beginning with the third edition. That editorial team would remain together through the 10th edition, assuring continuity and cohesiveness for the Pharmacotherapy project.
Our founding editors set several lofty goals for Pharmacotherapy. The work needed to meet the educational standards of emerging postbaccalaureate doctor of pharmacy programs, serve as an authoritative reference for clinical pharmacists and other clinicians involved in direct patient care, and support the recognition of pharmacotherapy as a board-certified specialty in pharmacy by providing evidence of the field’s unique and extensive body of knowledge. Those goals made the book an immediate success and have stood the test of time by guiding the editors for more than 30 years.
Turning to this 12th edition, the current editors met in Atlanta in early January 2020. Nearby, the Centers for Disease Control and Prevention was responding to the emergence of a novel pneumonia of unknown etiology. By the time we departed just two days later, Chinese authorities had identified and isolated a previously unknown coronavirus, then known as Wuhan-Hu-1. Despite the changes, challenges, illnesses, and losses the ensuing pandemic would bring, the editors and more than 300 authors of the 12th edition persevered to complete a record number of chapters (167) on time, online, and in print, including a new chapter regarding the ever-changing topic of COVID-19.
At that 2020 meeting, the editors decided to dive deeper into the digital world. Working with our publisher, we created a process for keeping online chapters updated on a continual basis, so they are current as new drugs are approved, guidelines are issued, and recommendations change on the best use of pharmacotherapeutic agents in prevention, management, and cure of diseases. Also, we published the 12th edition online in AccessPharmacy long before the print version could be released.
To handle this added responsibility, the editors needed help. A group of six assistant editors, each with unique expertise to complement that of the section editors, were recruited. Scott Bolesta (assisting Dr. DiPiro), Lisa Holle (Yee), Robert DiDomenico (Haines), Angela Bingham (Nolin), Amy VandenBerg (Ellingrod), and Rena Gosser (Posey) have provided invaluable assistance to the contributors and editors to produce the final manuscript for this 12th edition. We are pleased to acknowledge their efforts.
For the 12th edition, the editors chose not to make extensive changes in the chapter structure and content. One refinement was to replace the preclass and postclass learning activities that appeared in the 11th edition with a single “Beyond the Book” box placed at the beginning of each chapter. The intent is to prepare and stimulate learners by pointing them to multimedia resources that can deepen their understanding of the material.
Two of our founding editors are retiring from the book after the 12th edition. Drs. DiPiro and Yee have worked on all 12 editions and helped make this work the gold standard textbook in pharmacy and health professions education. The editors are pleased to welcome two new editors to the team: Jennifer Cocohoba, PharmD, MAS, of the University of California, San Francisco, for the chapters managed by Dr. DiPiro, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, of the University of Connecticut, for Dr. Yee’s chapters.
We acknowledge the many hours that numerous authors—including the many contributors since the first edition—have devoted to this labor of love. Without their dedication to the cause of improving pharmacotherapy and maintaining the accuracy, clarity, and relevance of their chapters, this text would unquestionably not be possible.
A special thanks go to Michael Weitz and Juanita Thompson of McGraw Hill and Poonam Bisht of MPS Limited for their input and support and for enhancing the online authoring tools needed to maintain the textbook on the AccessPharmacy website.
Many thanks to Terry Schwinghammer for his insights during our editor meetings and continued devotion to the Pharmacotherapy Casebook: A Patient-Focused Approach companion to this work and the tools, chapter updates, and innovations he has shepherded onto the AccessPharmacy website. Finally, we thank James Shanahan, Peter Boyle, and their colleagues at McGraw Hill for their ongoing support of the Pharmacotherapy family of resources, insights into publishing and higher education trends, and critical attention to detail.
The Editors, October 2022